



Transplant Diagnostics

Eurofins Transplant Diagnostics continues to develop a long-term data study utilizing TruGraf®

Transplant Genomics is pleased to report that the first patient samples from the TRULO ("TruGraf Long-term clinical Outcomes") study are being received and processed. TRULO is a prospective, multicenter observational registry study, designed to evaluate post-transplant clinical outcomes in recipients of kidney transplants who are undergoing serial TruGraf testing. This will be the first study to provide long-term data, beyond 2 years post-transplant, regarding the benefits of non-invasive surveillance of stable kidney transplant recipients to rule out silent subclinical rejection. TGI is on track to enroll 50 clinical sites and 2,000 patients in this post-transplant registry, which is unique in that it focuses on patients that are more remote from their transplant and will correlate TruGraf monitoring with long term outcomes. The information from this study has the potential to help improve long term survival of transplanted kidneys.

For questions or information regarding the TRULO study and TruGraf testing, contact info@trugraf.com.

TGI and Viracor Announce Transplant Advisory Board, to focus on trends and innovations in transplant diagnostics

Transplant Genomics, Inc. ("TGI") and Viracor Eurofins ("Viracor"), announce the formation of the Eurofins Transplant Medical and Scientific Advisory Board, employing diverse expertise and experience in transplantation and technology development to enhance the clinical value of diagnostics throughout the transplant community. Board members will focus on innovation and product development, utilizing their unique perspectives to help TGI and Viracor expand to serve the unmet needs in transplantation and guide future products—ultimately broadening the indications for **TruGraf** and **TRAC** transplant rejection biomarkers through clinical studies, R&D and the acquisition of additional disruptive technologies. The Board will be convened by Dr. John Holman, VP Medical Affairs at Eurofins – TGI.

Covering the breadth of geographies within the US market, the Board welcomes Dr. Roz Mannon, University of Nebraska; Dr. Michael Abecassis, University of Arizona; Dr. Fuad Shihab, University of Utah; Dr. Win Williams, Massachusetts General Hospital; Dr. Anil Chandraker, Brigham and Women's Hospital; Dr. Allan Kirk, Duke University (joining in August after completing his term as Editor-in-Chief of AJT); Dr. Jonathan Bromberg, University of Maryland, Dr. Robert Fairchild, Cleveland Clinic, and Dr. Matt Cooper, Georgetown University.

Advisor Dr. Johnathan Bromberg, Professor of Surgery and Microbiology and Immunology at the University of Maryland says "For too long transplant patients have had limited or invasive diagnostic

options, so it is tremendously exciting to join a Board with a mission in science and medicine to improve current diagnostic options available to transplant patients, and subsequently offer physicians better tools to alter and improve our approach to treatment”.

Advisor Dr. Michael Abecassis, Dean of the University of Arizona, College of Medicine – Tucson, says “The formation of this Board will help to expand the product portfolio to create new opportunities for the powerful commercial teams assembled by TGI and Viracor”. By combining TruGraf and TRAC, Eurofins has assembled the largest transplant diagnostics sales force, and has the most comprehensive portfolio of non-invasive kidney rejection tests available today, and is focused on aggressively growing beyond blood tests for kidney with more technologies and more organs. Combining this group expertise and Eurofin’s resources in research and development, this advisory board is uniquely positioned to drive clinical value throughout the transplant community.

For information on ordering tests and arranging remote sample collection, physicians may contact TGI about TruGraf tests by calling 1-844-TruGraf. Ordering and general information is also available on our websites at www.trugraf.com. For information on ordering or remote collection for TRAC or other Viracor products, please call 800.305.5198 or email info@viracor-eurofins.com.

About Eurofins - A global leader in bio-analysis

Eurofins Scientific, through its subsidiaries (hereinafter “Eurofins” or “the Group”), believes it is a global leader in food, environmental, pharmaceutical and cosmetics products testing and in agrosience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies. In addition, Eurofins is one of the leading global emerging players in esoteric clinical diagnostic testing. With over 47,000 staff across a network of more than 900 independent companies in over 50 countries generally specialized by end client markets and operating more than 800 laboratories, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services. The Group’s objective is to provide customers with high-quality and innovative services, accurate results on time and, when requested, expert advice by its highly-qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and a very large range of testing methods. As one of the most innovative and quality-oriented international companies in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities and healthcare practitioners around the world. Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

About Transplant Genomics Inc.

Transplant Genomics, Inc. (“TGI”) is a molecular diagnostics company committed to improving organ transplant outcomes, with an initial focus on kidney transplant recipients. Working with the transplant community, TGI is commercializing a suite of tests enabling diagnosis and prediction of transplant recipient immune status. Test results will support clinicians with information to optimize immune-suppressive therapy, enhance patient care and improve graft survival. Test services are offered through TGI’s CLIA laboratory in Pleasanton, CA. TGI was acquired by Eurofins in 2019.

About Viracor Eurofins

With over 30 years of specialized expertise in infectious disease, immunology and allergy testing for immunocompromised and critical patients, Viracor Eurofins is committed to helping medical professionals, transplant teams, reference laboratories and biopharmaceutical companies get results faster, when it matters most. Viracor is passionate about delivering value to its clients by providing timely, actionable information, never losing sight of the connection between the testing it performs and the patients it ultimately serves.

Viracor is a 100 percent subsidiary of Eurofins Scientific (EUFI.PA), the global leader in bio-analytical testing, and one of the world leaders in genomic services. For more information, please visit <https://www.eurofins.com/> and <https://www.viracor-eurofins.com/>.

Important disclaimer:

This blog post contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantee can be made as to their validity.